カバジタキセル
カバジタキセル 物理性質(zhì)
- 融點(diǎn) :
- 180 °C
- 沸點(diǎn) :
- 870.7±65.0 °C(Predicted)
- 比重(密度) :
- 1.31
- 貯蔵溫度 :
- Inert atmosphere,Store in freezer, under -20°C
- 溶解性:
- クロロホルム（微量）、DMSO（微量）、メタノール（微量）
- 外見(jiàn) :
- 白い固體。
- 酸解離定數(shù)(Pka):
- 11.20±0.46(Predicted)
- 色:
- ホワイトからオフホワイト
- 旋光度（Optical Rotation）:
- [α]/D -36 to -44°, c =0.5 in methanol
- InChIKey:
- BMQGVNUXMIRLCK-JACFBOAKNA-N
安全性情報(bào)
- リスクと安全性に関する聲明
- 危険有害性情報(bào)のコード(GHS)
| Sフレーズ |
24/25 |
|
|
| WGK Germany |
WGK 2 |
|
|
| HSコード |
29329990 |
|
|
| ストレージクラス |
11 - Combustible Solids |
|
|
| Hazard Classifications |
Acute Tox. 4 Oral
Muta. 2
Repr. 2
Skin Irrit. 2
STOT RE 2 |
|
|
| 絵表示（GHS） |
 
|
| 注意喚起語(yǔ) |
警告 |
| 危険有害性情報(bào) |
| コード |
危険有害性情報(bào) |
危険有害性クラス |
區(qū)分 |
注意喚起語(yǔ) |
シンボル |
P コード |
| H302 |
飲み込むと有害 |
急性毒性、経口 |
4 |
警告 |
|
P264, P270, P301+P312, P330, P501 |
| H315 |
皮膚刺激 |
皮膚腐食性/刺激性 |
2 |
警告 |
|
P264, P280, P302+P352, P321,P332+P313, P362 |
| H341 |
遺伝性疾患のおそれの疑い |
生殖細(xì)胞変異原性 |
2 |
警告 |
|
P201,P202, P281, P308+P313, P405,P501 |
| H373 |
長(zhǎng)期にわたる、または反復(fù)暴露により臓器の障 害のおそれ |
特定標(biāo)的臓器有害性、単回暴露 |
2 |
警告 |
|
P260, P314, P501 |
|
| 注意書(shū)き |
| P202 |
全ての安全注意を読み理解するまで取り扱わないこ と。 |
| P260 |
粉じん/煙/ガス/ミスト/蒸気/スプレーを吸入しないこ と。 |
| P264 |
取扱い後は皮膚をよく洗うこと。 |
| P264 |
取扱い後は手や顔をよく洗うこと。 |
| P301+P312 |
飲み込んだ場(chǎng)合：気分が悪い時(shí)は醫(yī)師に連絡(luò)する こと。 |
| P302+P352 |
皮膚に付著した場(chǎng)合：多量の水と石鹸で洗うこと。 |
| P308+P313 |
暴露または暴露の懸念がある場(chǎng)合：醫(yī)師の診斷/手當(dāng)てを 受けること。 |
|
| メーカー |
製品番號(hào) |
製品説明 |
CAS番號(hào) |
包裝 |
価格 |
更新時(shí)間 |
購(gòu)入 |
|
富士フイルム和光純薬株式會(huì)社(wako)
|
W01W0103-2508 |
カバジタキセル 98.0+% (HPLC)
Cabazitaxel 98.0+% (HPLC) |
183133-96-2 |
5mg |
￥9000 |
2024-03-01 |
購(gòu)入 |
|
東京化成工業(yè)
|
C3390 |
カバジタキセル >98.0%(HPLC)
Cabazitaxel
>98.0%(HPLC) |
183133-96-2 |
25mg |
￥12400 |
2023-06-01 |
購(gòu)入 |
|
東京化成工業(yè)
|
C3390 |
カバジタキセル >98.0%(HPLC)
Cabazitaxel
>98.0%(HPLC) |
183133-96-2 |
100mg |
￥36900 |
2023-06-01 |
購(gòu)入 |
|
Sigma-Aldrich Japan
|
SML2487 |
≥95% (HPLC)
Cabazitaxel ≥95% (HPLC) |
183133-96-2 |
5MG |
￥13600 |
2024-03-01 |
購(gòu)入 |
|
Sigma-Aldrich Japan
|
SML2487 |
≥95% (HPLC)
Cabazitaxel ≥95% (HPLC) |
183133-96-2 |
25MG |
￥55100 |
2024-03-01 |
購(gòu)入 |
カバジタキセル 化學(xué)特性,用途語(yǔ),生産方法
外観
白色～わずかにうすい褐色、結(jié)晶性粉末～粉末
溶解性
メタノール溶狀：試験適合
用途
ヨーロッパイチイの針狀葉か
ら抽出された 10- デアセチルバッカチンⅢか
ら半合成されたタキソイド系抗がん剤の有効
成分です。チューブリンの重合を促進(jìn)し、脫
重合を阻害することにより、細(xì)胞分裂を阻害
します。
効能
抗悪性腫瘍薬, 微小管脫重合阻害薬
説明
In June 2010, the U.S. FDA approved cabazitaxel (also referred to as
XRP6258 and RPR 116258A) in combination with the steroid prednisone
for the treatment of metastatic Castration-Resistant Prostate Cancer
(mCRPC) for patients who were previously treated with a docetaxelcontaining
regimen for late-stage disease.
Cabazitaxel is a semisynthetic analog of the
natural product taxol, which is isolated from the bark of the yew tree.
Cabazitaxel is a microtubule inhibitor that binds to the taxol-binding site of
tubulin. Similar to other tubulin inhibitors of the taxol class, cabazitaxel
inhibits microtubule disassembly resulting in mitotic blockade and cell
death. Docetaxel, also a semisynthetic taxol analog, was approved by the
FDA for the treatment of mCRPC in 2004. However, docetaxel is a substrate
for P-gp, which is thought to contribute to the constitutive and acquired
resistance of cancer cells to taxanes. Cabazitaxel has poor affinity for P-gp
and showed antitumor activity in preclinical in vitro studies and in vivo
tumor models that overexpress this protein. Cabazitaxel is synthesized on
a commercial scale from 10-deacetylbaccatin .
化學(xué)的特性
White solid
使用
Cabazitaxel (Jevtana, XRP6258) is a semi-synthetic derivative of a natural taxoid.
定義
ChEBI: A tetracyclic diterpenoid that is 10-deacetylbaccatin III having O-methyl groups attached at positions 7 and 10 as well as an O-(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hy
roxy-3-phenylpropanoyl group attached at position 13. Acts as a microtubule inhibitor, binds tubulin and promotes microtubule assembly and simultaneously inhibits disassembly.
臨床応用
Cabazitaxel was developed by Sanofi-Aventis as an intravenous injectable drug for the treatment of
hormone-refractory metastatic prostate cancer. As a microtubule inhibitor, cabazitaxel differs from docetaxel because it exhibits a much weaker affinity for P-glycoprotein (P-gp), an adenosine
triphosphate (ATP)-dependent drug efflux pump. Cancer cells that express P-gp become resistant
to taxanes, and the effectiveness of docetaxel can be limited by its high substrate affinity for P-gp.
Clinical studies confirmed that cabazitaxel retains activity in docetaxel-resistant tumors. Common
adverse events with cabazitaxel include diarrhea and neutropenia. Cabazitaxel in combination with
prednisone is an important new treatment option for men with docetaxel-refractory metastatic CRPC
(castration-resistant prostate cancer).
カバジタキセル 上流と下流の製品情報(bào)
原材料
Benzenepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-(1-ethoxyethoxy)-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4,6-dimethoxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)-
Benzenepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-[(tetrahydro-2H-pyran-2-yl)oxy]-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4,6-dimethoxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)-
1380584-07-5
N',O'-(4-Methoxybenzylidene)cabazitaxel
Cabazitaxel N-1
準(zhǔn)備製品
カバジタキセル 生産企業(yè)
Global( 543)Suppliers
カバジタキセル スペクトルデータ(1HNMR、13CNMR)
183133-96-2(カバジタキセル)キーワード:
- 183133-96-2
- (2AR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-acetoxy-9-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-
- TXD-258
- (αR,βS)-β-[[(1,1-DiMethylethoxy)carbonyl]aMino]-α-hydroxybenzenepropanoic Acid (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(Acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4,6-diMethoxy-4a,8,13,13-tetraMethyl-5-oxo-7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl Ester
- XRP 6258
- Cabazitaxel
- β-[[(1,1-DiMethylethoxy)carbonyl]aMino]-α-hydroxybenzenepropanoic Acid [2aR-[2aα,4β,4aβ,6β,9α(αR*,βS*),11α,12α,12aα,12bα]]-12b-(Acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4,6-diMethoxy-4a,8,13,13-tetraMethyl
- 7β, 10β-DiMethoxydocetaxel
- Cabazitaxel(XRP-6258)
- 7beta, 10beta-DiMethoxydocetaxel
- RPR-116258A
- taxoid XRP6258
- [2aR[2aalpha,4beta,4abeta,6beta,9alpha(2R,3S),11beta,12alpha,12aalpha,12balpha]]-12b-Acetoxy-9-[3-(tert-butoxycarbonylaMino)-2-hydroxy-3-phenylpropionyloxy]-12-(benzoyloxy)-11-hydroxy-4,6-diMethoxy-4a,8,13,13-tetraMethyl-2a,3,4,4a,5,6,9,10,11,12,12a,12b-d
- (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-acetoxy-9-(((2R,3S)-3-((tert-butoxycarbonyl)aMino)-2-hydroxy-3-phenylpropanoyl)oxy)-11-hydroxy-4,6-diMethoxy-4a,8,13,13-tetraMethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-Methanocyclodeca[3,4]be
- Benzenepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4,6-dimethoxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (αR,βS)-
- Cabazitaxel, >=98%
- XRP6258;RPR-116258A;TAXOID XRP6258;TXD 258
- CS-877
- Cabazitaxel 183133-96-2
- Benzenepropanoic acid, β-[[(1,1-dimethylethoxy)carbonyl]amino]-α-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4,6-dimethoxy-
- Cabazitaxel (This product is only available in Japan.)
- [2aR[2aalpha,4beta,4abeta,6beta,9alpha(2R,3S),11beta,12alpha,12aalpha,12balpha]]-12b-Acetoxy-9-[3-(tert-butoxycarbonylamino)-2-hydroxy-3-phenylpropionyloxy]-12-(benzoyloxy)-11-hydroxy-4,6-dimethoxy-4a
- Cabazitaxelum
- (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-Acetoxy-9-((3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-11-hydroxy-4,6-dimethoxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxet-12-yl benzoate
- Cabazitaxel USP/EP/BP
- 7β,10β-Dimethoxydocetaxel
- [2aR[2aalpha,4beta,4abeta,6beta,9alpha(2R,3S),11beta,12alpha...
- (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-Acetoxy-9-((3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-11-hydroxy-4,6-dimethoxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-
- CabazitaxelQ: What is
Cabazitaxel Q: What is the CAS Number of
Cabazitaxel Q: What is the storage condition of
Cabazitaxel Q: What are the applications of
Cabazitaxel
- Jevtana
- Cabazitaxel Injection
- カバジタキセル
- カバジタキセル アセトン付加物